Thailand intensifies control over anesthetics suspected in "zombie drug" cases
The Thai government has announced that etomidate, an intravenous anesthetic, will be reclassified as a Psychotropic Substance Category 2, effective from July 27. This decision comes in response to the misuse of etomidate in harmful vaping products known as "zombie pods," a problem that has been growing in Thailand and neighboring countries such as China, Hong Kong, and Taiwan.
The use of "zombie pods" that contain etomidate has led to cases of addiction and psychotropic reactions among users, raising concerns about public safety. Symptoms of etomidate overuse include intoxication-like effects, hand tremors, unsteadiness, anxiety, panic, sluggishness, and mental confusion.
To address this issue, the Ministry of Public Health has decided to reclassify etomidate to enhance regulatory oversight. As a Category 2 psychotropic substance, illegal possession will carry penalties of up to seven years in prison and/or a fine of up to 700,000 baht. Sellers could face up to 15 years in prison and/or a fine of up to 1.5 million baht.
The reclassification may lead to a shortage of etomidate for medical use. Medical centers are advised to stock up in advance since the substance will be available for purchase only through the Food and Drug Administration (FDA) starting from July 27. Dr Withid Sariddeechaikool, the deputy secretary-general of the FDA, made these statements on Thursday.
The rise of etomidate use in vaping products is linked to organized crime groups exploiting clinical-grade chemicals during disruptions in traditional drug supply chains, particularly during the COVID-19 pandemic. This shift has led to a significant increase in the use of such substances throughout Southeast and East Asia.
It is important to note that etomidate is currently regulated as a specially controlled substance and can only be used by doctors in medical centers for specific procedures or operations. The Thai authorities are taking decisive action to curb the misuse of this powerful drug and protect the public from its harmful effects.
The reclassification of etomidate as a Psychotropic Substance Category 2 raises concerns not only for public safety in the realm of health-and-wellness, but also for mental health, given the reported cases of addiction and psychotropic reactions among users. In response to the growing issue of etomidate misuse in harmful vaping products, the Thai authorities aim to enhance regulatory oversight, ensuring that this substance remains available for medical use while preventing its illicit distribution.
